American Herbal Products Association (AHPA) > Bookstore > Seminars

AHPA Sports Nutrition Congress

August 25-26, 2020 in Portland, Oregon

AHPA Hemp-CBD Supplement Congress

AHPA Hemp-CBD Supplement Congress

RESCHEDULED -- Aug. 26-27

Due to overwhelming demand, AHPA is presenting a second, expanded Hemp-CBD Supplement Congress in Portland, OR to provide companies with an understanding of federal and state legal and regulatory obligations and current issues and opportunities in the hemp-CBD market.

Webinar: Preparing for FDA cGMP Facility Inspections

Recorded December 17, 2019

This webinar is designed to help businesses in the dietary supplement industry understand the elements of current Good Manufacturing Practice (cGMP) regulations (21 CFR 111) that have been the primary focus of FDA inspections. This knowledge will assist businesses in better allocating and directing their compliance resources.

Webinar: Supplement cGMP Basics for Hemp-CBD Companies

Recorded Dec. 10, 2019 -- Duration: 2 hours

This webinar provides an overview of dietary supplement current good manufacturing (cGMP) requirements for hemp-CBD products. Legal and industry experts provide strategies and resources to comply and document compliance with  federal manufacturing requirements designed to ensure supplement product quality and safety.

Webinar: Compliance with FDA’s Revised Nutrition Labeling Regulations

Nutrition labeling requirements for foods and supplements scheduled to take effect January 1, 2020

Recorded October 29, 2019, this webinar offers expert insights into the nutrition labeling requirements for foods and dietary supplements are scheduled to take effect January 1, 2020 for manufacturers with $10 million or more in annual sales and January 1, 2021 for smaller manufacturers.

Webinar: Adverse Event Reports (AERs) and Recalls of Dietary Supplements

In-depth review of AER requirements and recent AER and recall data and trends

Dr. Rick Kingston, an industry expert with more than 35-years of experience, presents on serious adverse event report (SAER) data and observations. Ashish Talati, a partner with Amin Talati & Wasserman and one of the industry’s foremost experts on FDA regulatory matters, joins Dr. Kingston to review dietary supplement legal and regulatory SAER obligations. In addition, AHPA Chief Information Officer Dr. Merle Zimmermann presents an overview of recent FDA recall data.

Revised Hemp-CBD Status Report

How hemp and CBD companies are impacted by passage of the Farm Bill

Congress passed a Farm Bill in 2018 that included historic provisions to legalize hemp, the low THC cultivars of the Cannabis sativa L. species. This landmark legislation changes how hemp and hemp-derived products like cannabidiol (CBD) are regulated in the U.S. To help the herbal products industry understand the new regulatory landscape, AHPA has expanded this Status Report and to answer industry questions about the new legal landscape.

Free GRMA webinar on new ANSI-accredited auditing standards

Free GRMA webinar on new ANSI-accredited auditing standards

Webinar recording and handouts

AHPA partnered with the Global Retailer and Manufacturer Alliance (GRMA) to present this free webinar on February 26, 2019 to provide the herbal industry with specific details on the benefits and implementation costs of the new GRMA ANSI-accredited auditing standards.

Webinar: Prop 65 for Cannabis Products

Recorded January 16, 2019

Effective January 3, 2020, the Office of Environmental Health Hazard Assessment added cannabis (marijuana) smoke and Δ9-tetrahydrocannabinol (Δ9-THC) to the list of chemicals known to the state to cause reproductive toxicity (developmental endpoint) for purposes of California Proposition 65 (Prop 65). At a public meeting on December 11, 2019, the Developmental and Reproductive Toxicant Identification Committee (DARTIC) in its official capacity as the “state’s qualified experts” determined that cannabis (marijuana) smoke and Δ9-tetrahydrocannabinol (Δ9-THC) were shown to cause reproductive toxicity based on the developmental endpoint.

FDA Inspection Trends, cGMP Compliance Issues and Responding to an FDA 483

Two-part webinar recorded Dec. 4 and 18

Two-part webinar will provide data on recent FDA inspections, an overview of emerging compliance issues and strategies for responding to an FDA 483 in order to avoid an FDA warning letter.
RSS
123456

2020 Annual Fund Sponsors

   

AHPA appreciates the support of its sponsors, but does not endorse, recommend, or provide a warranty for any sponsor company, its products or services. AHPA has no responsibility for any transaction entered into with any of these companies.